Skip to main content
. Author manuscript; available in PMC: 2020 May 1.
Published in final edited form as: Cancer Immunol Res. 2019 Sep 4;7(11):1824–1836. doi: 10.1158/2326-6066.CIR-19-0299

Figure 6. The persistent clonotypes of TIL4095 had different gene expression profile compared to autologous TILs from four gastrointestinal cancer patients.

Figure 6.

A, Four patients with metastatic gastrointestinal cancers, 4007, 4069, 4071 and 4081, were treated with autologous TILs within the five-month window prior to the treatment of patient 4095. The ratio of persistence was calculated based on the percentage of neoantigen-specific T cells in PBLs at approximately one month after ACT, divided by the percentage of neoantigen-specific T cells in the infused TILs (Supplementary Table S6). B-E, Gene set enrichment analysis (GSEA) was performed to compare 4095 persistent clonotypes (9.2-P and 10-P) with TIL products from the four patients. Two gene sets, Persistance_Up and Persistance_Down, were used in the GSEA analysis. The Persistence_Up and Persistence_Down gene sets were constructed based on the shared, differentially expressed genes (FC > ±1.5, FDR<0.05), obtained from the comparisons of 9.1-NP vs 9.2-P and 9.1-NP vs 10-P (Supplementary Table S1). NES: normalized enrichment score.